Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SUDAFED 12 HOUR vs ACTIFED
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Pseudoephedrine is a sympathomimetic amine that acts as an agonist at alpha-1 and alpha-2 adrenergic receptors, causing vasoconstriction of nasal mucosa and reducing nasal congestion.
ACTIFED contains triprolidine, a first-generation antihistamine that competitively inhibits histamine H1 receptors, and pseudoephedrine, a sympathomimetic amine that directly stimulates alpha-adrenergic receptors, causing vasoconstriction and decongestion.
Temporary relief of nasal congestion due to common cold, hay fever, or other upper respiratory allergies
Temporary relief of symptoms associated with allergic rhinitis (sneezing, rhinorrhea, pruritus),Temporary relief of nasal congestion due to common cold, hay fever, or other upper respiratory allergies
120 mg orally every 12 hours, extended-release tablets. Maximum 240 mg per day.
1 tablet (pseudoephedrine HCl 60 mg, triprolidine HCl 2.5 mg) orally every 4-6 hours; maximum 4 tablets in 24 hours.
8-10 hours in adults with normal renal function; prolonged to 19-24 hours in renal impairment (Cr Cl <30 m L/min); shorter in children (3-4 hours)
Triprolidine: 3.2 hours; Pseudoephedrine: 5–8 hours (p H-dependent: alkaline urine prolongs). Terminal half-life for clinical use typically 4–6 hours.
Hepatic metabolism via N-demethylation to active metabolite; primarily excreted unchanged in urine
Triprolidine: Hepatic metabolism via CYP450 enzymes. Pseudoephedrine: Partially metabolized in liver by N-demethylation; excreted unchanged in urine (70-90%).
Renal: 74-95% as unchanged drug; 1-4% as active metabolite (norpsuedoephedrine); biliary/fecal: minimal (<1%)
Renal: 80% (20% unchanged, 60% as metabolites). Fecal: 20% (unchanged and metabolites). Active tubular secretion of pseudoephedrine.
50-60% bound (primarily to albumin and alpha-1-acid glycoprotein)
Triprolidine: 60% bound to serum albumin; Pseudoephedrine: 20–30% bound to plasma proteins (mainly albumin).
2.6-3.5 L/kg in adults; indicates extensive tissue distribution (higher than total body water)
Triprolidine: 2.5–4.0 L/kg; Pseudoephedrine: 2.6–3.5 L/kg. Indicates extensive tissue distribution.
Oral: 90-100% (immediate-release); sustained-release: approximately 95%
Oral: Triprolidine 90–100%; Pseudoephedrine 100% (first-pass metabolism negligible).
GFR 30-50 m L/min: reduce dose to 60 mg every 12 hours. GFR <30 m L/min: use is contraindicated.
Cr Cl 30-50 m L/min: extend dosing interval to every 8 hours. Cr Cl 15-29 m L/min: every 12 hours. Cr Cl <15 m L/min: not recommended.
Child-Pugh A: no adjustment. Child-Pugh B or C: consider reducing dose or extending interval due to reduced clearance; specific guidelines not established.
Child-Pugh A: no adjustment. Child-Pugh B: consider extending interval to every 8 hours. Child-Pugh C: avoid use.
Children 6-12 years: 60 mg orally every 12 hours; maximum 120 mg/day. Children <6 years: not recommended.
Children 6-12 years: 1/2 tablet (pseudoephedrine 30 mg, triprolidine 1.25 mg) orally every 6 hours; max 2 tablets/24 hours. Children <6 years: not recommended.
Start at lower end of dosing range (60 mg every 12 hours); monitor for CNS stimulation, hypertension, and urinary retention.
Start with 1/2 tablet (pseudoephedrine 30 mg, triprolidine 1.25 mg) orally every 8 hours; monitor for CNS excitation and anticholinergic effects.
None
None.
Cardiovascular effects: hypertension, palpitations, tachycardia,CNS stimulation: insomnia, nervousness, dizziness,Exacerbation of narrow-angle glaucoma,Exacerbation of prostatic hypertrophy/urinary retention,Diabetes mellitus: may increase blood glucose
Cardiovascular effects: hypertension, palpitations, tachycardia, arrhythmias,CNS stimulation: nervousness, dizziness, insomnia, especially in elderly,May cause urinary retention in patients with prostatic hypertrophy,Use caution in patients with diabetes, hyperthyroidism, ischemic heart disease, increased intraocular pressure,Anticholinergic effects: dry mouth, blurred vision, constipation
Severe hypertension,Coronary artery disease,Concurrent or recent (within 14 days) MAOI therapy,Narrow-angle glaucoma,Urinary retention
Hypersensitivity to triprolidine, pseudoephedrine, or any component,Severe hypertension or coronary artery disease,Monoamine oxidase inhibitor (MAOI) therapy (concurrent or within 14 days),Narrow-angle glaucoma,Urinary retention,During or within 14 days of MAOI use
Avoid caffeine-containing foods and beverages (coffee, tea, cola, chocolate) as they may increase central nervous system stimulation and exacerbate side effects like nervousness and insomnia. High-tyramine foods (aged cheeses, cured meats, fermented products) should be limited in patients taking MAOIs, but no direct interaction with pseudoephedrine alone. Alcohol may increase dizziness and should be avoided.
Avoid high-tyramine foods (aged cheese, cured meats, fermented products) as pseudoephedrine may potentiate vasopressor effects. Grapefruit juice may decrease pseudoephedrine absorption; separate administration by at least 4 hours.
Category C. First trimester: Possible risk of gastroschisis (limited data). Second and third trimesters: Uterine vasoconstriction, reduced placental perfusion; avoid due to risk of fetal hypoxia, tachycardia, and intrauterine growth restriction. No adequate well-controlled human studies.
FDA Pregnancy Category C. First trimester: Limited human data; animal studies show fetal toxicity at high doses. Avoid unless benefit outweighs risk. Second/third trimesters: Risk of premature labor, neonatal respiratory depression, and withdrawal symptoms with prolonged use. Use lowest effective dose for shortest duration.
Pseudoephedrine is excreted into breast milk (M/P ratio approximately 2.0-3.5). Use with caution: may reduce milk production and cause irritability in infants. Highest risk in preterm infants or those with impaired renal function. Avoid if possible; use lowest effective dose if necessary.
Pseudoephedrine is excreted into breast milk; M/P ratio approximately 3.5. Triprolidine is present in milk. Potential for irritability, sleep disturbance in infants; may reduce milk supply. Use with caution; alternative preferred. Discontinue breastfeeding or drug based on necessity.
No specific dose adjustment recommended, but use is generally avoided in pregnancy. If necessary, use immediate-release formulations at lowest effective dose for shortest duration. Extended-release formulations (e.g., 12-hour) are not recommended due to prolonged systemic exposure. Pharmacokinetic changes in pregnancy (increased volume of distribution, reduced plasma concentrations) may necessitate more frequent dosing, but safety data insufficient; avoid.
No specific dose adjustment recommended for pregnancy; however, increased plasma volume may reduce drug concentrations. Use lowest effective dose due to limited safety data. Avoid in hypertension or preeclampsia.
Pseudoephedrine is a sympathomimetic amine that causes vasoconstriction; avoid in patients with severe hypertension, coronary artery disease, or narrow-angle glaucoma. Extended-release formulation provides 12-hour symptom relief. Use with caution in patients with diabetes, hyperthyroidism, or prostatic hyperplasia. Monitor for nervousness, dizziness, or insomnia. Not recommended for use with MAOIs or within 14 days of stopping MAOIs.
Actifed (pseudoephedrine + triprolidine) is contraindicated in patients with severe hypertension, coronary artery disease, or narrow-angle glaucoma. Pseudoephedrine can cause CNS stimulation and insomnia, so avoid evening dosing. Triprolidine is a first-generation antihistamine with significant anticholinergic effects; use caution in elderly or those with BPH, urinary retention, or asthma.
Do not crush or chew the tablet; swallow whole with water.,Take with food or milk if stomach upset occurs.,Avoid taking within 4-5 hours of bedtime to prevent insomnia.,Do not exceed one tablet every 12 hours; maximum 2 tablets in 24 hours.,Discontinue and consult doctor if symptoms persist beyond 7 days or are accompanied by fever.,Avoid using other medications containing pseudoephedrine or other decongestants.,Do not use if you have high blood pressure, heart disease, or are taking MAOIs.
Do not take with other cold or allergy medications containing decongestants or antihistamines.,Avoid alcohol and sedatives as they may increase drowsiness.,Do not crush or chew extended-release tablets; swallow whole.,Monitor for increased blood pressure or heart rate; discontinue if palpitations occur.,May cause dizziness; avoid driving or operating heavy machinery until you know how it affects you.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SUDAFED 12 HOUR vs ACTIFED, answered by our medical review team.
SUDAFED 12 HOUR is a Decongestant that works by Pseudoephedrine is a sympathomimetic amine that acts as an agonist at alpha-1 and alpha-2 adrenergic receptors, causing vasoconstriction of nasal mucosa and reducing nasal congestion.. ACTIFED is a Decongestant/Antihistamine Combination that works by ACTIFED contains triprolidine, a first-generation antihistamine that competitively inhibits histamine H1 receptors, and pseudoephedrine, a sympathomimetic amine that directly stimulates alpha-adrenergic receptors, causing vasoconstriction and decongestion.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SUDAFED 12 HOUR and ACTIFED depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SUDAFED 12 HOUR is: 120 mg orally every 12 hours, extended-release tablets. Maximum 240 mg per day.. The standard adult dose of ACTIFED is: 1 tablet (pseudoephedrine HCl 60 mg, triprolidine HCl 2.5 mg) orally every 4-6 hours; maximum 4 tablets in 24 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SUDAFED 12 HOUR and ACTIFED in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SUDAFED 12 HOUR is classified as Category C. Category C. First trimester: Possible risk of gastroschisis (limited data). Second and third trimesters: Uterine vasoconstriction, reduced placental perfusion; avoid due to risk of. ACTIFED is classified as Category C. FDA Pregnancy Category C. First trimester: Limited human data; animal studies show fetal toxicity at high doses. Avoid unless benefit outweighs risk. Second/third trimesters: Risk . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.